Contact PR

To use this feature, join Babbler easily !

arrow_back

Babbler allows PR people and reporters to collaborate a better way.

By joining Babbler you will be able to access hundreds of newsrooms and PR contacts from your industrie(s) and also share with them your upcoming needs.

Their newsrooms are already on Babbler

You're 1 click away from signing up

Previous

Nice to see you again !

Press release

Bertrand Deluard appointed Chief Executive Officer of the Ethypharm Group
timer minutes reading time minute reading time

Copy link

Click to get original image size

St-Cloud, France 17 September 2018 – Ethypharm’s Supervisory Board is delighted to announce the appointment of Bertrand Deluard as Group CEO. This appointment takes effect on 1 October 2018.

Current President and CEO Hugues Lecat will remain the Group’s Executive President until the summer of 2019, and will then take over from Gilles Brisson as President of the Supervisory Board. We will still benefit from Gilles Brisson’s experience as he will remain a member of the Board.

Bertrand Deluard, who is 57, has more than 30 years’ experience within the drugs and medical devices industry, having worked for the biggest groups, both French (Rhône Poulenc, Aventis et Sanofi) and international (GSK, Johnson & Johnson, Cardinal Health). He thus has a strong background in general management within the various types of market in France and abroad. He was, until now, the Europe, Middle East and Africa President of the American company Cardinal Health, which he has expanded considerably over the past three years by means of organic growth and campaigns to boost external growth.

In the words of Hugues Lecat, “Bertrand was a natural choice for us to take the helm of the Group. His leadership, willingness to listen and ability to manoeuvre within complex environments are undeniable assets for Ethypharm’s ongoing transformation and growth.”

Bertrand Deluard himself says, “I feel immensely proud to be joining Ethypharm, and intend to accelerate the Group’s growth and internationalisation. A central part of this project is the focus on specific therapeutic domains in order to keep improving our response to the expectations and needs of patients and healthcare professionals.”


inscrit avec succès

Congratulations, you're registered on Babbler!

Discover now all the news waiting for you on Babbler: visit your newsfeed.!

Your topics have been selected, you can change it by clicking here